Detection of BK polyomavirus-associated nephropathy using plasma graft-derived cell-free DNA: Development of a novel algorithm from programmed monitoring

Jingyu Wen¹, Rongcun Sun²,³, Hongji Yang²,³,⁴, Qing Ran²,³,⁴ and Yifu Hou³,⁴*

¹Department of Medical Insurance, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China, ²School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, ³Department of Organ Transplantation, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China, ⁴Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province & Organ Transplantation Center, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu, China

Graft-derived cell-free DNA (GcfDNA) is a promising non-invasive biomarker for detecting allograft injury. In this study, we aimed to evaluate the efficacy of programmed monitoring of GcfDNA for identifying BK polyomavirus-associated nephropathy (BKPvAN) in kidney transplant recipients. We recruited 158 kidney transplant recipients between November 2020 and December 2021. Plasma GcfDNA was collected on the tenth day, first month, third month, and sixth month for programmed monitoring and one day before biopsy. \( \Delta \text{GcfDNA (cp/mL)} \) was obtained by subtracting the baseline GcfDNA (cp/mL) from GcfDNA (cp/mL) of the latest programmed monitoring before biopsy. The receiver operating characteristic curve showed the diagnostic performance of GcfDNA (cp/mL) at biopsy time and an optimal area under the curve (AUC) of 0.68 in distinguishing pathologically proven BKPvAN from pathologically unconfirmed BKPvAN. In contrast, \( \Delta \text{GcfDNA (cp/mL)} \) had a sensitivity and specificity of 80% and 84.6%, respectively, and an AUC of 0.83. When distinguishing clinically diagnosed BKPvAN from clinically excluded BKPvAN, the AUC of GcfDNA (cp/mL) was 0.59 at biopsy time, and \( \Delta \text{GcfDNA (cp/mL)} \) had a sensitivity and specificity of 81.0% and 76.5%, respectively, and an AUC of 0.81. Plasma GcfDNA (cp/mL) was not significantly different between TCMR [0.15 (0.08, 0.24) cp/mL] and pathologically proven BKPvAN[0.34 (0.20, 0.49) cp/mL]. In conclusion, we recommend programmed monitoring of plasma GcfDNA levels after a kidney transplant. Based on our findings from the programmed monitoring, we have developed a novel algorithm that shows promising results in identifying and predicting BKPvAN.
Introduction

BK polyomavirus (BKPyV) infection frequently causes BK polyomavirus-associated nephropathy (BKPyVAN) in up to 10% of kidney transplant recipients (KTRs) (1). BKPyV is a significant risk factor for kidney allograft dysfunction and loss among KTRs (2). The primary method for detecting BKPyV infection is quantitative polymerase chain reaction (PCR) to detect BKPyV DNA in urine and plasma. However, the PCR results cannot be used for diagnosing BKPyVAN. The diagnosis of BKPyVAN relies on the histopathological detection of simian virus 40 (SV40) in kidney biopsy tissues. However, this has several disadvantages, including invasive procedures, high false-negative rates, and sampling errors. In other words, a negative anti-SV40 stain does not exclude BKPyVAN, especially when infected renal tubules cannot be obtained or no significant infection has been formed in the renal cortex, which will affect the accuracy of pathology. Therefore, some cases cannot be diagnosed by pathological biopsy. At the same time, some kidney transplant centers do not perform kidney graft biopsies as part of their routine follow-up procedures. Therefore, non-invasive biomarkers are urgently needed to assist in the diagnosis of BKPyVAN.

Graft-derived cell-free DNA (GcfDNA) originates from allografts and is considered a potential noninvasive marker for evaluating graft injury, especially in distinguishing antibody-mediated rejection (ABMR) (3–10). As with graft rejection, graft injury caused by BKPyV may also lead to increased GcfDNA levels in the urine or blood. Apart from BKPyV, there is little research on the relationship of GcfDNA levels with other viruses such as Cytomegalovirus or Epstein–Barr virus after kidney transplantation (11). Chen et al. reported that urine GcfDNA concentration in BKPyVAN was higher than that in T cell-mediated rejection (TCMR), borderline change, and negative biopsies (12). Chen et al. reported that elevated urine GcfDNA levels may help to distinguish BKPyVAN in kidney transplant recipients with BKPyV viruria (13). Kant et al. suggested that GcfDNA may be a useful noninvasive test to assess progression of BKPyV to BKPyVAN (14). BKPyVAN can induce moderate increases in GcfDNA (15). Goussous et al. suggested that elevations in GcfDNA are not specific to kidney allograft rejection and can be associated with BK viremia affecting the transplanted kidney (16). However, these studies mainly focused on urine GcfDNA, which is associated with poor reproducibility and a low DNA extraction rate, and were primarily assessed on a “for-cause” basis but not a “for-protocol” basis. More importantly, GcfDNA tends to rise before clinical symptoms, so it may not be appropriate to assess GcfDNA when BKPyV-related kidney injury is suspected.

Thus far, the role of plasma GcfDNA in the diagnosis of BKPyVAN has not been confirmed. We performed this study to investigate the value of plasma GcfDNA level in programmed monitoring and during BKPyV infection. The diagnostic capabilities of plasma GcfDNA in BKPyVAN were further analyzed and used to develop algorithms to detect BKPyVAN.

Materials and methods

Study design and patients

We enrolled primary KTRs at the organ transplant center of Sichuan Provincial People’s Hospital (Chengdu, China). The inclusion criteria were as follows: (a) adult male or female aged > 18 years and (b) voluntary participation with informed consent. The exclusion criteria were as follows: (a) multi-organ transplant, (b) repeated kidney transplant, (c) severe pneumonia, (d) refusal to participate in the study, and (e) loss to follow-up. Urine BKPyV infection in our study included patients with urine BKPyV load > 3 log10 copies/mL. Those with urine BKPyV DNA load > 7 log10 copies/mL would undergo further kidney biopsy to confirm the diagnosis of BKPyVAN (biopsy cohort). Written informed consent was obtained from all the patients. Kidney allografts from living or deceased organ donors who met the ethical guidelines for kidney donation were used in this study. No kidney transplant recipients received donor organs from executed prisoners or other institutionalized individuals. This study adhered to the tenets of the Declaration of Helsinki and was approved by the Ethics Committee of the Sichuan Provincial People’s Hospital (No. 2020405).

Sample collection and DNA extraction

For each recipient, 10 mL peripheral blood samples were collected regularly on the tenth day (D10), first month (M1), third month (M3), and sixth month (M6) after transplantation. For KTRs who were diagnosed with a urine BKPyV DNA load > 7 log10 copies/mL during the...
Quantification of GcfDNA

The fractional abundance (%) and genomic copies per mL plasma (cp/mL) of the GcfDNA were measured using a technical testing service called “YiLeShu-Graft sentinel®” by S&KM Biotechnology Co., Ltd. GcfDNA fractions (%) were calculated using the following formula:

\[
\text{GcfDNA fraction} = \frac{\text{Dimer cDNA}}{\text{Total cDNA} - \text{GcfDNA} - \text{haploid GcfDNA}} 
\]

Absolute quantification of haploid GcfDNA genomic copies per mL plasma (cp/mL) is calculated by multiplying the total concentration of cfDNA (cp/mL) in a sample by the GcfDNA fraction (%). The concentration of the total cfDNA is determined by a digital droplet PCR. The assay was performed using the Bio-Rad QX200 Droplet Digital System (Bio-Rad Laboratories, US), and the data were processed using QuantaSoft™ version 1.7.4 software (Bio-Rad Laboratories, US).

Diagnosis of BKPyVAN

The pathological diagnosis of BKPyVAN is according to the 2019 American Society of Transplantation guidelines in (Table 1) (17). Proven BKPyVAN will also be referred to as pathologically proven BKPyVAN, and the other categories will be considered as pathologically unconfirmed BKPyVAN. Pathological lesions were scored according to the 2017 Banff criteria (18). The pathological features of BKPyVAN were classified using the American Society for Transplantation schema; BKPyVAN was classified as stage A, B, or C, based on the Banff guidelines published by Hirsch et al. (19).

| Pathological diagnose | Urine BKPyV DNA load | Plasma BKPyV DNA load | Anti-SV40 IHC stain |
|----------------------|----------------------|-----------------------|--------------------|
| possible BKPyVAN     | > 7 log10 copies/mL  | negative              | negative           |
| probable BKPyVAN     | > 7 log10 copies/mL  | > 3 log10 copies/mL in two measurements within 3 weeks | negative           |
| presumptive BKPyVAN  | > 7 log10 copies/mL  | > 4 log10 copies/mL in at least one of two measurements in < 3 weeks | negative           |
| proven BKPyVAN       | > 7 log10 copies/mL  | > 4 log10 copies/mL in at least one of two measurements in < 3 weeks | positive           |

BKPyVAN, BK polymavirus-associated nephropathy; BK polymavirus; IHC, immunohistochemistry.
clinical variables and early GcfDNA. The predictions were then compared with the actual diagnosis of BKPyVAN to assess the effectiveness of the predictions. These were used to develop algorithms to predict BKPyVAN using GcfDNA. Statistical analyses were performed using GraphPad Prism 8.0 and R version 4.0.3. All statistical tests adopted a 95% confidence interval (95% CI) and a two-tailed value of P< 0.05, indicating statistical significance.

Results

Patients and samples

A flow diagram depicting the criteria used for patient inclusion is shown in Figure 1. A total number of 158 recipients with 672 plasma GcfDNA samples were included. The study data were collected until May 2022, with a median follow-up time of 325 (264, 408) days. The baseline information and indications between all patients and those with BKPyV infection were compared, and plasma GcfDNA (cp/mL) and GcfDNA (%) were not significantly different (Table 2).

According to the biopsy results, 17 were possible BKPyVAN, 9 were presumptive BKPyVAN, and 14 were proven BKPyVAN. No patient was diagnosed with probable BKPyVAN during the study period. Based on clinical judgment, in addition to 14 proven BKPyVAN, 2 out of 17 possible BKPyVAN and 2 out of 9 presumptive BKPyVAN were classified as clinically diagnosed BKPyVAN (n = 18). Serum creatinine levels before kidney transplant in the proven BKPyVAN group [85.8 (66.93, 124.2) μmol/L] were comparable to those in the presumptive BKPyVAN group [69.4 (52.3, 112.8) μmol/L, P = 0.53] but greater than those in the possible BKPyVAN group [42.9 (41.2, 51.7) μmol/L, P< 0.001, P = 0.01]. The warm ischemia time (WIT) in the proven BKPyVAN group [11 (5.5, 14.75) min] was similar to that in the presumptive BKPyVAN group [8 (6, 12) min (P = 0.58)] but significantly higher than that in the possible BKPyVAN group [2 (2, 5) min (P = 0.006)]. The cold ischemia time (CIT) in the possible BKPyVAN group [230 (120, 480) min] was comparable to that in the presumptive BKPyVAN group.
group [360 (240, 500) min (P = 0.33)] but was significantly lower than that in the proven BKPyVAN group [790 (440, 900) min (P = 0.007, P = 0.03)] (Table 3).

**TABLE 2** Patient characteristic.

| Characteristic | All patients (n=158) | BKPyV infection patients (n=55) | P* |
|----------------|----------------------|-------------------------------|----|
| **Baseline information** |                      |                               |    |
| Age (years), donors, median (IQR) | 49 (39, 54) | 49 (44, 54) | 0.973 |
| Age (years), recipients, mean ± SD | 36 (28, 46) | 38 (30, 45.5) | 0.866 |
| Serum creatinine levels before kidney transplant (µmol/L), median (IQR) | 63.5 (43, 108.2) | 65.7 (43.3, 90.35) | 0.747 |
| WIT (min), median (IQR) | 6 (2, 14) | 7 (2, 14.5) | 0.922 |
| CIT (min), median (IQR) | 450 (180, 945) | 400 (180, 740) | 0.326 |
| Donor type, n (%) | 32 (15%) | 6 (2.8%) | 0.294 |
| DBD | 63 (29.6%) | 24 (11.3%) | 0.972 |
| DCD | 63 (29.6%) | 25 (11.7%) | 0.972 |
| Indication for kidney transplant, n (%) |                      |                               | 0.302 |
| IgA nephropathy | 12 (5.6%) | 2 (0.9%) | 0.972 |
| Nephrotic syndrome | 84 (39.4%) | 39 (18.3%) | 0.972 |
| Chronic glomerulonephritis | 2 (0.9%) | 0 (0%) | 0.972 |
| Diabetic nephropathy | 1 (0.5%) | 0 (0%) | 0.972 |
| Others | 11 (5.2%) | 2 (0.9%) | 0.972 |
| Not available | 48 (22.5%) | 12 (5.6%) | 0.972 |
| GcfDNA (cp/mL), median (IQR) |                      |                               |    |
| D10 | 0.64 (0.38, 1.00) | 0.84 (0.47, 1.10) | 0.142 |
| M1 | 0.48 (0.29, 0.70) | 0.48 (0.36, 0.75) | 0.281 |
| M3 | 0.45 (0.22, 0.67) | 0.45 (0.20, 0.76) | 0.606 |
| M6 | 0.32 (0.17, 0.54) | 0.28 (0.16, 0.55) | 0.848 |
| GcfDNA (%), median (IQR) |                      |                               |    |
| D10 | 0.61 (0.40, 0.90) | 0.7 (0.40, 0.89) | 0.883 |
| M1 | 0.44 (0.30, 0.70) | 0.50 (0.40, 0.78) | 0.135 |
| M3 | 0.40 (0.20, 0.60) | 0.35 (0.18, 0.60) | 0.475 |
| M6 | 0.31 (0.20, 0.60) | 0.30 (0.20, 0.70) | 0.628 |

WIT, warm ischemia time; CIT, cold ischemia time; DBD, donor after brain death; DCD, donor after cardiac death; LD, living donor; BKPyV, BK polyomavirus; GcfDNA, graft-derived cell-free DNA.

*Comparison between all patients and BKPyV infection patients.

Plasma GcfDNA (cp/mL) and GcfDNA (%) at biopsy time

At biopsy time, the median GcfDNA (cp/mL) in the proven BKPyVAN group [0.90 (0.63–1.06) cp/mL] was comparable to that in the presumptive BKPyVAN group [0.80 (0.70–1.05) cp/mL] but was significantly higher than in the possible BKPyVAN group [0.52 (0.42–0.78) cp/mL (P = 0.037) (Figure 2A)]. However, no significant differences in median GcDNA (%) were found between the possible BKPyVAN [0.75 (0.33–1.00%)], presumptive BKPyVAN [0.65 (0.53–0.70%)], and proven BKPyVAN [0.78 (0.59–1.03%)] groups (Figure 2B). Based on the patients’ creatinine levels, we divided them into a normal creatinine group (≤ 104 µmol/L) and an abnormal creatinine group (> 104 µmol/L). Our results revealed that there were no significant differences in plasma GcfDNA (cp/mL) (Figure 2C) and GcfDNA (%) (Figure 2D) between the normal and abnormal creatinine groups (P > 0.05).

Diagnostic performance of plasma GcfDNA in BKPyVAN

The ROC curve showed the diagnostic performance of both GcfDNA (cp/mL) [AUC = 0.68, 95% CI: 0.51–0.85] and GcfDNA (%) [AUC = 0.62, 95% CI: 0.45–0.80] at biopsy time in distinguishing pathologically proven BKPyVAN from pathologically unconfirmed BKPyVAN. Moreover, the sensitivity and specificity of GcfDNA (cp/mL) were 92.9% and 46.2%, respectively, at a cutoff value of 0.57 cp/mL (Figure 3A). GcfDNA (%) had a cut-off value of 0.43%, with 92.9% sensitivity and 26.9% specificity (Figure 3B). The ROC curve showed the diagnostic performance of both GcfDNA (cp/mL) (Figure 3C).
TABLE 3  Characteristic of possible BKPyVAN, presumptive BKPyVAN, and proven BKPyVAN patients.

| Characteristic                        | Possible BKPyVAN (n=17) | Presumptive BKPyVAN (n=9) | Proven BKPyVAN (n=14) | P*  |
|--------------------------------------|-------------------------|--------------------------|-----------------------|-----|
| **Donor-associated parameters**      |                         |                          |                       |     |
| Age (years), mean ± SD               | 49.29 ± 11.64           | 47.33 ± 4.95             | 49 ± 10.36            | 0.889|
| Sex, n (%                           |                         |                          |                       | 0.009|
| Female                               | 3 (7.5%)                | 3 (7.5%)                 | 10 (25%)              |     |
| Male                                 | 14 (35%)                | 6 (15%)                  | 4 (10%)               |     |
| BMI (kg/m²), mean ± SD              | 23.07 ± 3.16            | 22.49 ± 2.99             | 22.73 ± 3.28          | 0.899|
| Donor type, n (%)                   |                         |                          |                       | < 0.001|
| DBD                                  | 0 (0%)                  | 1 (2.5%)                 | 5 (12.5%)             |     |
| DCD                                  | 3 (7.5%)                | 6 (15%)                  | 6 (15%)               |     |
| LD                                   | 14 (35%)                | 2 (5%)                   | 3 (7.5%)              |     |
| Serum creatinine levels before kidney transplant (µmol/L), median (IQR) | 42.9 (41.2, 51.7)       | 69.4 (52.3, 112.8)       | 85.8 (66.93, 124.2)   | 0.001|
| WIT (min), median (IQR)             | 2 (2, 5)                | 8 (6, 12)                | 11 (5.5, 14.75)       | 0.015|
| CIT (min), median (IQR)             | 230 (120, 480)          | 360 (240, 500)           | 790 (440, 900)        | 0.012|
| **Recipient-associated parameters**  |                         |                          |                       |     |
| Age (years), mean ± SD               | 32.47 ± 7.32            | 36.44 ± 9.11             | 42.64 ± 9.05          | 0.007|
| Sex, n (%)                           |                         |                          |                       | 0.078|
| Female                               | 9 (22.5%)               | 4 (10%)                  | 2 (5%)                |     |
| Male                                 | 8 (20%)                 | 5 (12.5%)                | 12 (30%)              |     |
| BMI (kg/m²), median (IQR)           | 19.86 (18.37, 22.84)    | 22.32 (18.91, 22.64)     | 22.54 (20.69, 23.34)  | 0.276|
| **Matching parameters**              |                         |                          |                       |     |
| HLA-MM, n (%)                        |                         |                          |                       | < 0.001|
| 0-3                                  | 16 (40%)                | 2 (5%)                   | 4 (10.0%)             |     |
| 4-6                                  | 1 (2.5%)                | 7 (17.5%)                | 10 (25.0%)            |     |
| DSA, n (%)                           |                         |                          |                       | 0.695|
| No                                   | 16 (40%)                | 8 (20%)                  | 14 (35%)              |     |
| Yes                                  | 1 (2.5%)                | 1 (2.5%)                 | 0 (0%)                |     |
| **Induction agent**                  |                         |                          |                       | 0.533|
| Basiliximab, n (%)                   |                         |                          |                       |     |
| No                                   | 4 (10%)                 | 1 (2.5%)                 | 1 (2.5%)              |     |
| Yes                                  | 13 (32.5%)              | 8 (20%)                  | 13 (32.5%)            |     |
| r-ATG, n (%)                         |                         |                          |                       | 0.258|
| No                                   | 13 (32.5%)              | 9 (22.5%)                | 13 (32.5%)            |     |
| Yes                                  | 4 (10%)                 | 0 (0%)                   | 1 (2.5%)              |     |
| Rituximab, n (%)                     |                         |                          |                       | 1.000|
| No                                   | 16 (40%)                | 9 (22.5%)                | 13 (32.5%)            |     |
| Yes                                  | 1 (2.5%)                | 0 (0%)                   | 1 (2.5%)              |     |

BMI, body mass index; DBD, donor after brain death; DCD, donor after cardiac death; LD, living donor; WIT, warm ischemia time; CIT, cold ischemia time; HLA-MM, human leukocyte antigen mismatching; DSA, donor specific antibody; r-ATG, rabbit-antithymocyte globulin. *Comparison among possible BKPyVAN, presumptive BKPyVAN and proven BKPyVAN.

[AUC = 0.59, 95% CI: 0.41–0.77] and GcfDNA (%) (Figure 3D) [AUC = 0.56, 95% CI: 0.38–0.74] at biopsy time in distinguishing clinical diagnosed BKPyVAN from clinical excluded BKPyVAN.

It is widely recognized that GcfDNA elevation precedes clinical manifestations. We presume that this is the same for BKPyV infections. Therefore, we attempted to trace GcfDNA data before biopsy time. We focused on the latest programmed monitoring of GcfDNA (cp/mL) before biopsy time and baseline of GcfDNA (cp/mL) and found that 76.92% (30/39) of programmed monitoring values before biopsy were increased; plasma GcfDNA of programmed monitoring time and biopsy time of possible BKPyVAN, presumptive BKPyVAN, and proven BKPyVAN recipients are summarized in Supplementary Table 1. Therefore, we defined the individual change in GcfDNA ($\Delta$GcfDNA) (cp/mL) to describe this increase. The formula used to calculate the change in GcfDNA is as follows:
ΔGcfDNA(cp/mL) = GcfDNA(cp/mL) of the latest programmed monitoring time before biopsy time – Baseline GcfDNA(cp/mL)

Two cases were excluded from the analysis: one patient was diagnosed with proven BKPyVAN on day 5 (baseline GcfDNA not available), and another patient was diagnosed with presumptive BKPyVAN on day 339 (long interval from programmed monitoring). The ROC curve showed that the diagnostic performance of ΔGcfDNA (cp/mL) had a sensitivity and specificity of 80% and 84.6%, respectively, when distinguishing pathologically proven BKPyVAN from pathologically unconfirmed BKPyVAN (AUC = 0.83) (Figure 4A), and a sensitivity and specificity of 81% and
76.5%, respectively, when distinguishing clinically diagnosed BKPyVAN from clinical excluded BKPyVAN (AUC = 0.81) (Figure 4B).

Plasma ΔGcfDNA (cp/mL) in BKPyVAN and TCMR

It is known that the pathological changes of BKPyVAN and TCMR sometimes show many similarities, making the differential diagnosis very difficult. We wondered if ΔGcfDNA (cp/mL) could help distinguish them. Eight patients were diagnosed as biopsy-proven TCMR, We found programmed monitoring values before biopsy were also increased in the TCMR group, but plasma ΔGcfDNA (cp/mL) was not significantly different between TCMR [0.15 (0.08, 0.24) cp/mL] and pathologically proven BKPyVAN[0.34 (0.20, 0.49) cp/mL] (Figure 5).

Plasma ΔGcfDNA (cp/mL) in BKPyVAN and TCMR

GcfDNA (cp/mL) is a predictor for pathologically proven BKPyVAN

In our previous studies, we found that early GcfDNA can predict eGFR values 90 days post-transplant (20). Furthermore, we intended to explore the efficacy of GcfDNA (cp/mL) of the first programmed monitoring (at D10) in predicting pathologically proven BKPyVAN. Consequently, we included relevant clinical variables (recipient age, donor age, serum creatinine level before transplant, WIT, CIT, HLA-MM, and
creatinine level at D10) and GcfDNA (cp/mL) at D10 for LASSO regression analysis. LASSO regression was used to eliminate clinical variables that might overfit the model. We found that according to the coefficient distribution, recipients’ age, serum creatinine level before transplant, CIT, and GcfDNA (cp/mL) at D10 were included for model construction (Supplementary Figure 1 and Supplementary Table 2). Our results revealed that the use of the LASSO regression model obtained high AUC values (0.89, 95% CI = 0.79–0.98) when predicting pathologically proven BKPyVAN, and the sensitivity and specificity were 0.93 and 0.69, respectively (Supplementary Figure 2A). The AUC of the LASSO regression model using clinical variables alone was 0.84 (Supplementary Figure 2B).

Table 2. Our results revealed that the use of the LASSO regression model obtained high AUC values (0.89, 95% CI = 0.79–0.98) when predicting pathologically proven BKPyVAN, and the sensitivity and specificity were 0.93 and 0.69, respectively (Supplementary Figure 2A). The AUC of the LASSO regression model using clinical variables alone was 0.84 (Supplementary Figure 2B).

FIGURE 4
The discrimination capacity of ∆GcfDNA(cp/mL). Receiver operating curves of (A) ∆GcfDNA(cp/mL) for distinguishing pathologically proven BKPyVAN (proven BKPyVAN) from pathologically unconfirmed BKPyVAN (possible BKPyVAN+ presumptive BKPyVAN); (B) ∆GcfDNA(cp/mL) for distinguishing clinically diagnosed BKPyVAN from clinical excluded BKPyVAN.

FIGURE 5
Comparison of ∆GcfDNA(cp/mL) between TCMR and pathologically proven BKPyVAN. BKPyVAN, BK polyomavirus-associated nephropathy; TCMR, T cell-mediated rejection.
We further performed multivariate logistic regression to investigate whether GcfDNA alone had a predictive value. We include recipient age, donor age, serum creatinine level before transplant, WIT, CIT, HLA-MM, and creatinine level at D10 and GcfDNA at D10 in the model. And the multivariate logistic regression shows that GcfDNA at D10 (P = 0.007, OR = 13.04, 95% CI, 2.01–84.38) and HLA-MM (P = 0.021, OR = 7.92, 95% CI, 1.37–45.70) are independent predictors (Supplementary Table 3).

Discussion

Plasma or urine GcfDNA levels can be used as non-invasive markers of kidney transplant injury; during ABMR, graft-damaged vascular endothelial cells directly release large amounts of GcfDNA into the circulation, followed by a simultaneous increase in plasma GcfDNA (cp/mL) and GcfDNA (%) (6, 7, 21). On the other hand, when BKPyV infection occurs in KTRs, changes in plasma GcfDNA (cp/mL) and GcfDNA (%) are less pronounced than those in ABMR, with only sporadic data reporting an abnormal rise (6, 10, 22–24). This is consistent with our findings, where we found that plasma GcfDNA (cp/mL) and GcfDNA (%) were not significantly elevated in 55 patients with BKPyV infection during the follow-up period. A likely reason for this is that BKPyV infection mainly causes damage to the renal tubular epithelium, and the GcfDNA released from the renal tubules does not enter the circulatory system until the development of BKPyVAN; therefore, the elevation of plasma GcfDNA is not significant. Many studies have suggested the use of urine GcfDNA for the diagnosis of BKPyVAN, and a study by Chen et al. has suggested that increased urine GcfDNA concentration is significantly correlated with BKPyVAN (12). However, the selection of urine GcfDNA has several limitations. First, cfDNA is easily decomposed and not easily preserved; the internal environment of urine is far less stable than that of blood, and its stable extraction is more challenging. Second, the volume of urine varies from patient to patient at different testing points in time, resulting in poor reproducibility of urine GcfDNA results. Finally, when combined with urinary tract infection, the total urine cfDNA is significantly elevated. Therefore, the GcfDNA test results are severely interfered with and do not accurately reflect the actual situation of kidney transplant damage due to BKPyV infection (25). Therefore, plasma GcfDNA rather than urine GcfDNA should be used to more accurately reflect the actual damage to the kidney transplant in BKPyVAN.

Our results were consistent with those reported by Chen (13), that plasma GcfDNA (cp/mL) was more diagnostic efficient than GcfDNA percentage (9, 26). With an AUC of 0.68 for pathologically proven BKPyVAN and an AUC of 0.62 for clinically diagnosed BKPyVAN, the ability of GcfDNA (cp/mL) at biopsy time to diagnose BKPyVAN was still relatively poor. As we know, subclinical injury is common among KTR and BKPyV infections and can cause graft damage before any clinical symptom, such as proteinuria or worsening creatinine (27). Therefore, it may not be appropriate to assess GcfDNA “for cause”. To further explore the use of plasma GcfDNA (cp/mL) in the diagnosis of BKPyVAN, we compared the changes in GcfDNA (cp/mL) values at the biopsy time and time of programmed monitoring. Interestingly, when compared to the baseline GcfDNA (cp/mL), 76.9% (30/39) of the programmed monitoring time GcfDNA (cp/mL) started to increase before biopsy time. The results support our hypothesis that GcfDNA (cp/mL) at the biopsy time is not a good representation of the onset of renal injury in BKPyVAN, and abnormal elevation of GcfDNA (cp/mL) caused by BKPyVAN should occur earlier. Moreover, to quantify the degree of this elevation, the baseline levels of GcfDNA should also be considered.

Considering patients’ programmed monitoring of GcfDNA on D10, M1, M3, and M6, we proposed a new algorithm for ΔGcfDNA (cp/mL), which is obtained by subtracting the baseline GcfDNA (cp/mL) from the measured GcfDNA (cp/mL) of the latest programmed monitoring time before biopsy time. The results showed that the diagnostic performance of ΔGcfDNA (cp/mL) has a better discriminatory ability for the diagnosis of BKPyVAN than GcfDNA (cp/mL) at the biopsy time, regardless of the diagnostic criteria of pathologically proven BKPyVAN or clinically diagnosed BKPyVAN. This result further suggests that BKPyVAN injury occurs before clinical manifestations and that programmed monitoring of plasma GcfDNA (cp/mL) may help identify kidney transplant injury earlier, thereby triggering earlier kidney biopsy and therapeutic intervention.

Shen et al. (28) found that urine GcfDNA can distinguish between BKPyVAN and type I TCMR. However, our results suggest that plasma ΔGcfDNA (cp/mL) cannot distinguish TCMR from pathologically proven BKPyVAN. This is also in line with the theory that GcfDNA is not specific to kidney allograft rejection which may be affected by different types of injury, the severity of the injury, and the detection time. In addition, the pathological changes of BKPyVAN and TCMR sometimes show many similarities, making the differential diagnosis very difficult. In other words, without information on virus load and dosage of an immunosuppressive agent, we question the practical value of GcfDNA in distinguishing between BK infection and TCMR. Moreover, a recent review suggests a threshold of 0.5% be considered for indicating TCMR (29). Our results showed that 29/40 patients with BKPyV infection have higher GcfDNA levels than 0.5% at biopsy time. This phenomenon again proves that GcfDNA cannot distinguish TCMR from pathologically proven BKPyVAN.

Early prediction of BKPyVAN can greatly improve its treatment outcomes. To our knowledge, this is the first study that combined clinical features with GcfDNA (cp/mL) to develop an algorithmic model for predicting BKPyVAN. Previous kidney transplant prediction models have been
developed based on multiple sets of clinical data and algorithms, which could inform clinicians regarding graft rejection, graft acceptance, and patient survival (30). In the present study, using the LASSO regression model, which included clinical variables and GcfDNA biomarkers, we found that the clinical variables combined with GcfDNA (cp/mL) of the first programmed monitoring were better predictors of postoperative pathologically proven BKPyVAN than the clinical variables alone. Our results provide a new strategy for assessing and predicting various complications such as BKPyVAN after kidney transplantation. However, more data are required to validate this prediction model. Should the validation be successful, we expect to achieve real-time monitoring of individualized graft health after kidney transplant in clinical applications to improve the long-term survival of allogeneic kidney transplant recipients.

The main limitation of this study is that the number of patients recruited from a single hospital with a concurrent diagnosis of BKPyVAN was low, which requires the continued expansion of the cohort. Patients with multiorgan transplants, repeated kidney transplants, and severe pneumonia were not included in this study; therefore, these findings need to be extrapolated to these patients with caution.

In conclusion, this study found that plasma GcfDNA (cp/mL) and GcfDNA (%) in BKPyV-infected recipients did not differ significantly from all transplant patients in programmed monitoring. However, they showed significant elevation in proven BKPyVAN. Moreover, GcfDNA (cp/mL) has a low diagnostic efficacy for BKPyVAN at biopsy time. Our novel algorithms based on programmed monitoring, ΔGcfDNA (cp/mL), and the LASSO regression model show promising results in identifying and predicting BKPyVAN.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by Ethics Committee of the Sichuan Provincial People’s Hospital (No.2020405). The patients/participants provided their written informed consent to participate in this study.

Author contributions

JW and YH conceived the study. RS and HY collected the data. JW and QR analyzed the data. JW wrote the manuscript. YH, HY, and QR reviewed and revised the manuscript. All authors contributed to the article and approved the submitted version.

Funding

The study was supported by the “key R&D projects of Department of Science and Technology Sichuan Provincial” (no. 2022YFS0093) and “Youth Fund of Sichuan Provincial People’s Hospital” (no. 2022QN26).

Acknowledgments

The authors thank Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, for their support of this work and the reviewers for allowing us to make improvements to the manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.1006970/full#supplementary-material

References

1. Sawinski D, Goral S. BK virus infection: an update on diagnosis and treatment. Nephrology dialysis Transplant Off Publ Eur Dialysis Transplant Assoc - Eur Renal Assoc (2015) 30(2):209–17. doi: 10.1093/ndt/gfu023

2. Yi SG, Knight RJ, Lunsford KE. BK virus as a mediator of graft dysfunction following kidney transplantation. Curr Opin Organ Transplant (2017) 22(4):320–7. doi: 10.1097/MOT.0000000000000429
guidelines from the American society of transplantation infectious diseases

Donor-derived cell-free DNA in infections in kidney transplant recipients: Case T, et al. Levels of donor-derived cell-free DNA and chemokines in BK polyomavirus-e622. doi: 10.1097/TXD.0000000000001061

the prediction of BK virus-associated nephropathy.

Front Immunol

nephropathy in kidney transplant recipients with BK polyomavirus infection.

Causes of renal allograft injury in recipients with normal donor-derived cell-free DNA via massively multiplex PCR. J Clin Med (2018) 8(1):19. doi: 10.3390/jcm8010019

Diagnostic application of kidney allograft-derived absolute cell-free DNA levels during transplant dysfunction. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surgeons (2019) 19(4):1037–49. doi: 10.1111/ajt.15142

11. Xie WY, Kim K, Gousseu N, Drachenberg CB, Scalea JR, Weir MR, et al. Causal role of renal allograft injury in recipients with normal donor-derived cell-free DNA. Transplant direct (2021) 7(4):e679. doi: 10.1097/TXD.0000000000001135

12. Chen XT, Qiu J, Wu ZX, Zhang H, Chen Y, Yang SC, et al. Use of both plasma and urine donor-derived cell-free DNA to identify various renal allograft injuries. Clin Chem (2022) 68(6):814–25. doi: 10.1373/clinchem.hcva053

13. Chen XT, Chen WF, Li J, Deng RH, Huang Y, Yang SC, et al. Urine donor-derived cell-free DNA helps discriminate BK polyomavirus-associated nephropathy in kidney transplant recipients with BK polyomavirus infection. Front Immunol (2020) 11:1763. doi: 10.3389/fimmu.2020.01763

14. Kant S, Bromberg J, Haas M, Brennan D. Donor-derived cell-free DNA and the prediction of BK virus-associated nephropathy. Transplant direct (2020) 6(11): e622. doi: 10.1097/TXD.0000000000001061

15. Mayer KA, Omic H, Weselinklinder I, Deborer K, Renni-Schlaighofer R, Viant T, et al. Levels of donor-derived cell-free DNA and chemokines in BK polyomavirus-associated nephropathy. Clin Transplant (2022) 27(4):e14785. doi: 10.1111/cttr.14785

16. Gousseu N, Xie W, Doveney N, Scalea JR, Bartosic A, Haritun A, et al. Donor-derived cell-free DNA in infections in kidney transplant recipients. Case series. Transplant direct (2020) 6(7):e658. doi: 10.1097/TXD.0000000000001019

17. Hirsch HH, Randhawa PS. BK polyomavirus in solid organ transplantation. Clin Transplant (2020) 34(9):e13528. doi: 10.1111/ctr.13528

18. Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D, et al. The banff 2017 kidney meeting report: Revised diagnostic criteria for chronic active T-cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surgeons (2018) 18(2):293–307. doi: 10.1111/ajt.14625

19. Hirsch HH, Randhawa P. BK polyomavirus in solid organ transplantation. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surgeons (2013) 13 Suppl 4:179–88. doi: 10.1111/ajt.12110

20. Di W, Ran Q, Yang H, Lu J, Hou Y, Wang X, et al. Use of graft-derived cell-free DNA as a novel biomarker to predict allograft function after kidney transplantation. Int J Urol Off J Japanese Urological Assoc (2021) 28(10):1019–25. doi: 10.1111/iju.14638

21. Huang E, Sethi S, Peng A, Najjar R, Mirocha J, Haas M, et al. Early clinical experience using donor-derived cell-free DNA to detect rejection in kidney transplant recipients. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surgeons (2019) 19(6):1663–70. doi: 10.1111/ajt.15289

22. Shen J, Zhou Y, Chen Y, Li X, Lei W, Ge J, et al. Dynamics of early post-operative plasma ddcfDNA levels in kidney transplantation: a single-center pilot study. Transplant Int Eur Soc Organ Transplant (2019) 32(2):184–92. doi: 10.1111/tit.13544

23. Bu L, Gupta G, Pai A, Anand S, Stites E, Moiidaddin I, et al. Clinical outcomes from the assessing donor-derived cell-free DNA monitoring insights of kidney allografts with longitudinal surveillance (ADMIRAL) study. Kidney Int (2022) 101(4):793–803. doi: 10.1016/j.kint.2021.11.034

24. Giels EM, Ledegang RJ, Dendooven A, Meyersen P, Beirnaert C, Laukens K, et al. The use of plasma donor-derived, cell-free DNA to monitor acute rejection after kidney transplantation. Nephrology dialysis Transplant Off Publ Eur Dialysis Transplant Assoc - Eur Renal Assoc (2020) 35(4):714–21. doi: 10.1093/ndta/gta091

25. Burnham P, Dadhania D, Heyang M, Chen F, Westblade LF, Suthanthiran M, et al. Urinary cell-free DNA is a versatile analyte for monitoring infections of the urinary tract. Nat Commun (2018) 9(1):2412. doi: 10.1038/s41467-018-04745-y

26. Sun K, Jiang P, Chan KC, Wong J, Cheng YK, Liang RH, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci United States America (2015) 112(40):E1002286. doi: 10.1073/pnas.1508736112

27. Lubetzky ML, Salinas T, Schwartz JE, Suthanthiran M. Urinary cell mRNA profiles predictive of human kidney allograft status. Clin J Am Soc Nephrol CJASN (2021) 16(10):1565–77. doi: 10.2215/CJN.14010820

28. Shen J, Guo L, Lei W, Liu S, Yan P, Liu H, et al. Urinary donor-derived cell-free DNA as a non-invasive biomarker for BK polyomavirus-associated nephropathy. J Zhejiang Univ Sci B (2021) 22(11):917–28. doi: 10.1631/jzus.B2100131

29. Kant S, Brennan DC. Donor derived cell free DNA in kidney transplantation: The circa 2020-2021 update. Transplant Int Off J Eur Soc Organ Transplant (2022) 35:10448. doi: 10.1016/j.trim.2021.10.1044

30. Tapak L, Hamidi O, Amini P, Poorajal J. Prediction of kidney graft rejection using artificial neural network. Healthcare Inf Res (2017) 23(4):277–84. doi: 10.4258/hir.2017.23.4.277